Dual therapy with an angiotensin receptor blocker and a JAK1/2 inhibitor attenuates dialysate-induced angiogenesis and preserves peritoneal membrane structure and function in an experimental CKD rat model

By sjmartinez • April 5, 2023

Zhang P, Miyata KN, Nast CC, LaPage JA, Mahoney M, Nguyen S, Khan K, Wu Q, Adler SG, Dai T. Dual therapy with an angiotensin receptor blocker and a JAK1/2 inhibitor attenuates dialysate-induced angiogenesis and preserves peritoneal membrane structure and function in an experimental CKD rat model. Perit Dial Int. 2023 Mar;43(2):159-167. doi: 10.1177/08968608221116956. Epub 2022 Aug 9. PMID: 35946050.

Tags: Angiogenesis, fibrosis, Harbor UCLA, JAK inhibitor, Nephrology, peritoneal dialysis, peritoneal membrane, Publications

Facilitators and challenges in the implementation of the Care Ecosystem at six clinical sites in the United States: A qualitative study

Sideman AB, Merrilees J, Dulaney S, Allawala M, Barclay M, Rosenbloom M, Hanson LR, Ward KT, Hess M, Olney NT, Lum HD, Sawyer RJ, Possin[...]

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani[...]